For CRC patients who have metastasis or are unable to undergo a complete resection, an accurate and noninvasive assessment of the KRAS gene mutation status is helpful in guiding a targeted drug therapy and optimizing clinical decision-making (25). This evidence concerns the gene KRAS and colorectal carcinoma.